Altimmune (ALT)
(Real Time Quote from BATS)
$7.15 USD
+0.07 (0.99%)
Updated Apr 25, 2024 03:20 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALT 7.15 +0.07(0.99%)
Will ALT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALT
Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade
Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?
ALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study
Altimmune (ALT) Rises 7% on Completing Dosing in Obesity Study
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval
Other News for ALT
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
3 Potential Biopharma Buyout Targets
Alternus Clean Energy, Inc. Announces Closing of $2.16 Million Private Placement of Convertible Notes and Warrants
13 new obesity drugs could hit the market by 2029 amid surging demand
Interesting ALT Put And Call Options For December 20th